Equity and Quality of Global CKD Care - what are we waiting for?
Am J Nephrol. 2023 Dec 18. doi: 10.1159/000535864. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is an important but insufficiently recognized public health problem. Unprecedented advances in delaying progression of CKD and reducing kidney failure and death have been made in recent years, with the addition of the sodium glucose co-transporter 2 inhibitors and other newer medication to the established standard of care with inhibitors of the renin angiotensin system. Despite knowledge of these effective therapies, their prescription and use remains suboptimal globally, and more specially in low resource settings...
Source: American Journal of Nephrology - December 18, 2023 Category: Urology & Nephrology Authors: Valerie A Luyckx Ayah Elmaghrabi Manisha Sahay Nicole Scholes-Robertson Laura Sola Tobias Speare Elliot K Tannor Katherine Tuttle Ikechi G Okpechi Source Type: research
Equity and Quality of Global CKD Care - what are we waiting for?
Am J Nephrol. 2023 Dec 18. doi: 10.1159/000535864. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is an important but insufficiently recognized public health problem. Unprecedented advances in delaying progression of CKD and reducing kidney failure and death have been made in recent years, with the addition of the sodium glucose co-transporter 2 inhibitors and other newer medication to the established standard of care with inhibitors of the renin angiotensin system. Despite knowledge of these effective therapies, their prescription and use remains suboptimal globally, and more specially in low resource settings...
Source: American Journal of Nephrology - December 18, 2023 Category: Urology & Nephrology Authors: Valerie A Luyckx Ayah Elmaghrabi Manisha Sahay Nicole Scholes-Robertson Laura Sola Tobias Speare Elliot K Tannor Katherine Tuttle Ikechi G Okpechi Source Type: research
Equity and Quality of Global CKD Care - what are we waiting for?
Am J Nephrol. 2023 Dec 18. doi: 10.1159/000535864. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is an important but insufficiently recognized public health problem. Unprecedented advances in delaying progression of CKD and reducing kidney failure and death have been made in recent years, with the addition of the sodium glucose co-transporter 2 inhibitors and other newer medication to the established standard of care with inhibitors of the renin angiotensin system. Despite knowledge of these effective therapies, their prescription and use remains suboptimal globally, and more specially in low resource settings...
Source: American Journal of Nephrology - December 18, 2023 Category: Urology & Nephrology Authors: Valerie A Luyckx Ayah Elmaghrabi Manisha Sahay Nicole Scholes-Robertson Laura Sola Tobias Speare Elliot K Tannor Katherine Tuttle Ikechi G Okpechi Source Type: research
Association Between Serum Klotho and All-Cause Mortality in Chronic Kidney Disease: Evidence From a Prospective Cohort Study
CONCLUSION: This study documented a distinctive "L"-shaped association between serum Klotho levels and all-cause mortality among individuals with CKD. Further research is needed to validate these findings.PMID:38104542 | DOI:10.1159/000535808 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 17, 2023 Category: Urology & Nephrology Authors: Shisheng Han Xiaolu Zhang Xiaojun Wang Yi Wang Yanqiu Xu Li Shang Source Type: research
Association Between Serum Klotho and All-Cause Mortality in Chronic Kidney Disease: Evidence From a Prospective Cohort Study
CONCLUSION: This study documented a distinctive "L"-shaped association between serum Klotho levels and all-cause mortality among individuals with CKD. Further research is needed to validate these findings.PMID:38104542 | DOI:10.1159/000535808 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 17, 2023 Category: Urology & Nephrology Authors: Shisheng Han Xiaolu Zhang Xiaojun Wang Yi Wang Yanqiu Xu Li Shang Source Type: research
Serum phosphorus management with sucroferric oxyhydroxide as a first-line phosphate binder within the first year of hemodialysis
CONCLUSIONS: Among patients on hemodialysis, initiating SO as a first-line PB resulted in significant reductions in sP while maintaining a relatively low PB pill burden.PMID:38091973 | DOI:10.1159/000535754 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 13, 2023 Category: Urology & Nephrology Authors: Juan A Medaura Meijiao Zhou Linda H Ficociello Michael S Anger Stuart M Sprague Source Type: research
Serum phosphorus management with sucroferric oxyhydroxide as a first-line phosphate binder within the first year of hemodialysis
CONCLUSIONS: Among patients on hemodialysis, initiating SO as a first-line PB resulted in significant reductions in sP while maintaining a relatively low PB pill burden.PMID:38091973 | DOI:10.1159/000535754 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 13, 2023 Category: Urology & Nephrology Authors: Juan A Medaura Meijiao Zhou Linda H Ficociello Michael S Anger Stuart M Sprague Source Type: research
Serum phosphorus management with sucroferric oxyhydroxide as a first-line phosphate binder within the first year of hemodialysis
CONCLUSIONS: Among patients on hemodialysis, initiating SO as a first-line PB resulted in significant reductions in sP while maintaining a relatively low PB pill burden.PMID:38091973 | DOI:10.1159/000535754 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 13, 2023 Category: Urology & Nephrology Authors: Juan A Medaura Meijiao Zhou Linda H Ficociello Michael S Anger Stuart M Sprague Source Type: research
Mortality rates and a clinical predictive model for the elderly on maintenance hemodialysis: A large observational cohort study of 17,354 Asian patients
CONCLUSIONS: Hemodialysis is appropriate for patients aged 70-80 years. A risk score for mortality in patients aged ≥80 years has been developed. The score is based on seven readily obtainable and evaluable clinical characteristics.PMID:38071974 | DOI:10.1159/000535669 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 10, 2023 Category: Urology & Nephrology Authors: Kajohnsak Noppakun Surapon Nochaiwong Apichat Tantraworasin Jiraporn Khorana Paweena Susantitaphong Adisorn Lumpaopong Suchai Sritippayawan Vuddhidej Ophascharoensuk Chidchanok Ruengorn Source Type: research
Mortality rates and a clinical predictive model for the elderly on maintenance hemodialysis: A large observational cohort study of 17,354 Asian patients
CONCLUSIONS: Hemodialysis is appropriate for patients aged 70-80 years. A risk score for mortality in patients aged ≥80 years has been developed. The score is based on seven readily obtainable and evaluable clinical characteristics.PMID:38071974 | DOI:10.1159/000535669 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 10, 2023 Category: Urology & Nephrology Authors: Kajohnsak Noppakun Surapon Nochaiwong Apichat Tantraworasin Jiraporn Khorana Paweena Susantitaphong Adisorn Lumpaopong Suchai Sritippayawan Vuddhidej Ophascharoensuk Chidchanok Ruengorn Source Type: research
Mortality rates and a clinical predictive model for the elderly on maintenance hemodialysis: A large observational cohort study of 17,354 Asian patients
CONCLUSIONS: Hemodialysis is appropriate for patients aged 70-80 years. A risk score for mortality in patients aged ≥80 years has been developed. The score is based on seven readily obtainable and evaluable clinical characteristics.PMID:38071974 | DOI:10.1159/000535669 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 10, 2023 Category: Urology & Nephrology Authors: Kajohnsak Noppakun Surapon Nochaiwong Apichat Tantraworasin Jiraporn Khorana Paweena Susantitaphong Adisorn Lumpaopong Suchai Sritippayawan Vuddhidej Ophascharoensuk Chidchanok Ruengorn Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
